ClinicalTrials.gg
RecruitingNCT07271771DENMUSINUpdated Dec 15, 2025

The Effect of Denosumab on Muscle and Strength and Insulin Sensitivity

A Phase 4 interventional study of Denosumab and Saline (0.9% NaCl) in Osteoporosis, sponsored by Aarhus University Hospital. Recruiting at 1 site in Denmark. Open to female participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-12-15.

Sponsored by Aarhus University Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled May 2024, registered Nov 2025).
  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
40 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies testing denosumab in Osteoporosis — 8 open to participants now, 11 under way, 2 of them phase 3. Denosumab · Osteoporosis.

Planned enrollment
41st of 64
40 · median 90
Started
2024
with 4 others
Phase 4
19 of 64
5 open now
Primary completion
2027-03
later than 6 of 10 live
Registered
62nd of 64
by date
Lead sponsor
1 of 64
Aarhus University Hospital

Among the 64 studies testing denosumab in Osteoporosis, this one is the 41st largest by planned enrollment, is one of 5 that started in 2024, is one of 19 in phase 4, reaches primary completion later than 6 of the 10 other live ones, and was the 62nd registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

8 of the 64 studies testing denosumab in Osteoporosis are open now, in 8 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 40 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing denosumab in Osteoporosis, or all of them as a file.
02

Study summary

Randomized, placebo controlled prospective trial evaluating the effect of denosumab on insulin sensitivity and muscle strength.

Read the detailed description

Denosumab is an antibody against receptor-activator of nuclear factor kappa-B ligand (RANKL) that prevents recruitment and differentiation of mature osteoclasts. Treatment with denosumab markedly decreases bone resorption, increases bone mineral density (BMD), and reduces the risk of vertebral as well as non-vertebral and hip fractures. Osteoclasts produce dipeptidyl peptidase-4 (DPP-4) that degrades glucagon-like peptide-1 (GLP-1) and GLP-1 stimulates insulin production. In accordance with this, animal models have shown a beneficial effect of denosumab on glucose metabolism. However, data from clinical studies in patients with osteoporosis are limited and the results inconsistent. In a small, randomised trial with 52 healthy postmenopausal women, treatment with denosumab for 12 months reduced DPP-4 and increased GLP-1 compared to placebo but no effect was seen on insulin or fasting glucose levels. In the same publication, the authors conducted a non-randomized, observational study in osteoporotic patients with diabetes mellitus or prediabetes that were treated with either denosumab, bisphosphonates, or calcium + vitamin D at the discretion of their physician. Here, treatment with denosumab significantly reduced fasting glucose after 6 months and HbA1c after 12 months compared to bisphosphonates or calcium + vitamin D. Similar findings were seen in another observational study with 20 patients with diabetes. On the other hand, a post hoc analysis of the FREEDOM trial did not find a general effect of denosumab on fasting glucose in postmenopausal women with self-reported diabetes or prediabetes, but only reported a small decrease in fasting glucose in denosumab treated women with diabetes not treated with antidiabetics. This is in line with three small observational studies, in which no clinically relevant effect of denosumab on fasting glucose, insulin level or homeostatic model assessment for insulin resistance (HOMA-IR) was identified.

Overall, the heterogeneity across the studies is large, most of the trials are observational studies and the results are inconsistent. Therefore, randomized, controlled trials are warranted to further elucidate this.

Denosumab has also been shown to improve muscle strength compared to placebo in animal models, however, data from human studies is limited. In an observational study, denosumab decreased the risk of falls and improved sarcopenia measures in 135 patients with osteoporosis compared to 272 patients treated with alendronate or zoledronate assessed at treatment initiation and after 5 years for denosumab and alendronate and 3 years for zoledronate. All outcome measures worsened one years after denosumab discontinuation. In another prospective observational study with 18 postmenopausal women, denosumab treatment for an average of three years improved appendicular lean mass and handgrip strength compared to treatment with bisphosphates or placebo. This is in line with two additional observational studies, in which denosumab improved muscle strength after 6 - 17 months compared to bisphosphonates or vitamin D.

None of the studies evaluating the effect of denosumab on muscle strength are randomised controlled trials, the outcome measures are different and the follow up visits few. Also, none of the studies controlled for exercise.

The investigators therefore want to conduct a randomized, placebo controlled prospective trial evaluating the effect of denosumab on insulin sensitivity and muscle strength.

03

Conditions studied

  • Osteoporosis

Keywords

  • muscle
  • insulin sensitivity
  • denosumab
  • bone mineral density
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women (postmenopausal for at least two years)
  • Age ≥ 40 years
  • BMD T-score ≥ -2.0 (lumbar spine, total hip or femoral neck)
  • At least 2 lumbar vertebrae that can be evaluated by dual-energy x-ray absorptiometry (DXA)
  • Diabetes Mellitus type 2
  • Treatment with metformin as monotherapy

Exclusion criteria

Exclusion Criteria:

  • Treatment for osteoporosis at any time
  • Other antidiabetic medication than metformin
  • Low-energy vertebral fractures at any time
  • Low-energy hip fracture at any time
  • Ongoing treatment with systemic
  • Metabolic bone disease (for example osteogenesis imperfecta, Paget's disease of bone, hyperparathyroidism)
  • Treatment affecting bone, calcium metabolism or muscle
  • Active cancer within the last 5 years with the exception of basal cell skin cancer
  • Estimated (eGFR) ≤ 35 mL/min
  • Unable to read and understand Danish
  • Immobility
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Study group 1

    Denosumab

    Drug: Denosumab

  • Placebo comparator
    Study group 2

    Placebo

    Drug: Saline (0.9% NaCl)

Interventions

  • Denosumab 60 mg

  • DrugSaline (0.9% NaCl)

    Placebo

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Insulin sensitivity: HbA1c

    Changes in Hb1Ac (mmol/mol) from baseline to month 12

    Time frame: 12 months

  2. Insulin sensitivity: HOMA-IR

    Changes in HOMA-IR from baseline to month 12

    Time frame: 12 months

  3. Insulin sensitivity: fasting glucose

    Changes in fasting glucose (mmol/l) from baseline to month 12

    Time frame: 12 months

  4. Insulin sensitivity: oral glucose tolerance test

    Changes in oral glucose tolerance test (OGTT) (mmol/l) from baseline to month 12

    Time frame: 12 months

  5. Muscle mass

    Changes in muscle mass (kg) from baseline to month 12.

    Time frame: 12 months

  6. Muscle strength

    Changes in muscle strength (N) from baseline to month 12.

    Time frame: 12 months

Secondary outcomes

  1. DPP-4

    Changes in DPP-4 (U/L) from baseline to month 12.

    Time frame: 12 months

  2. GLP-1

    Changes in GLP-1 (pmol/L) from baseline to month 12.

    Time frame: 12 months

  3. Bone turnover markers: CTX

    Changes in carboxy-terminal collagen crosslinks (CTX) (ug/l) from baseline to month 12.

    Time frame: 12 months

  4. Bone turnover markers: PINP

    Changes in procollagen type I N-terminal propeptide (PINP) (ug/L) from baseline to month 12.

    Time frame: 12 months

  5. Bone Mineral Density

    Change in lumbar spine BMD (g/cm2) from baseline to month 12.

    Time frame: 12 months

  6. Advanced glycation end products (AGEs)

    Change in advanced glycation end products (AGEs) from baseline to month 12.

    Time frame: 12 months

  7. Muscle strength

    Changes in muscle strength (N) from baseline to month 1 and 3.

    Time frame: Month 1 and 3

  8. Insulin sensitivity: Hb1Ac month 1 and 3

    Changes in Hb1Ac (mmol/mol) from baseline to month 1 and 3

    Time frame: Month 1 and 3

  9. Insulin sensitivity: HOMA-IR month 1 and 3

    Changes in HOMA-IR from baseline to month 1 and 3

    Time frame: Month 1 and 3

  10. insulin sensitivity: fasting glucose month 1 and 3

    Changes in fasting glucose (mmol/l) from baseline to month 1 and 3

    Time frame: Month 1 and 3

  11. Insulin sensitivity: OGTT month 1 and 3

    Changes in oral glucose tolerance test (OGTT) (mmol/l) from baseline to month 1 and 3

    Time frame: Month 1 and 3

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Makras P. Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial. J Bone Miner Res. 2019 Dec;34(12):2220-2228. doi: 10.1002/jbmr.3853. Epub 2019 Oct 14. PubMed 31433518 ↗
  • Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008 Aug;43(2):222-229. doi: 10.1016/j.bone.2008.04.007. Epub 2008 Apr 26. PubMed 18539106 ↗
  • Rupp T, von Vopelius E, Strahl A, Oheim R, Barvencik F, Amling M, Rolvien T. Beneficial effects of denosumab on muscle performance in patients with low BMD: a retrospective, propensity score-matched study. Osteoporos Int. 2022 Oct;33(10):2177-2184. doi: 10.1007/s00198-022-06470-3. Epub 2022 Jun 25. PubMed 35751664 ↗
  • Phu S, Bani Hassan E, Vogrin S, Kirk B, Duque G. Effect of Denosumab on Falls, Muscle Strength, and Function in Community-Dwelling Older Adults. J Am Geriatr Soc. 2019 Dec;67(12):2660-2661. doi: 10.1111/jgs.16165. Epub 2019 Sep 4. No abstract available. PubMed 31483858 ↗
  • Miedany YE, Gaafary ME, Toth M, Hegazi MO, Aroussy NE, Hassan W, Almedany S, Nasr A, Bahlas S, Galal S; Egyptian Academy of Bone Health, Metabolic Bone Diseases. Is there a potential dual effect of denosumab for treatment of osteoporosis and sarcopenia? Clin Rheumatol. 2021 Oct;40(10):4225-4232. doi: 10.1007/s10067-021-05757-w. Epub 2021 May 19. PubMed 34008069 ↗
  • Rossini A, Frigerio S, Dozio E, Trevisan R, Perseghin G, Corbetta S. Effect of Denosumab on Glucose Homeostasis in Postmenopausal Women with Breast Cancer Treated with Aromatase Inhibitors: A Pilot Study. Int J Endocrinol. 2020 Nov 6;2020:1809150. doi: 10.1155/2020/1809150. eCollection 2020. PubMed 33204260 ↗
  • Lasco A, Morabito N, Basile G, Atteritano M, Gaudio A, Giorgianni GM, Morini E, Faraci B, Bellone F, Catalano A. Denosumab Inhibition of RANKL and Insulin Resistance in Postmenopausal Women with Osteoporosis. Calcif Tissue Int. 2016 Feb;98(2):123-8. doi: 10.1007/s00223-015-0075-5. Epub 2015 Oct 24. PubMed 26498169 ↗
  • Passeri E, Benedini S, Costa E, Corbetta S. A Single 60 mg Dose of Denosumab Might Improve Hepatic Insulin Sensitivity in Postmenopausal Nondiabetic Severe Osteoporotic Women. Int J Endocrinol. 2015;2015:352858. doi: 10.1155/2015/352858. Epub 2015 Mar 19. PubMed 25873952 ↗
  • Napoli N, Pannacciulli N, Vittinghoff E, Crittenden D, Yun J, Wang A, Wagman R, Schwartz AV. Effect of denosumab on fasting glucose in women with diabetes or prediabetes from the FREEDOM trial. Diabetes Metab Res Rev. 2018 May;34(4):e2991. doi: 10.1002/dmrr.2991. Epub 2018 Apr 16. PubMed 29430796 ↗
  • Abe I, Ochi K, Takashi Y, Yamao Y, Ohishi H, Fujii H, Minezaki M, Sugimoto K, Kudo T, Abe M, Ohnishi Y, Mukoubara S, Kobayashi K. Effect of denosumab, a human monoclonal antibody of receptor activator of nuclear factor kappa-B ligand (RANKL), upon glycemic and metabolic parameters: Effect of denosumab on glycemic parameters. Medicine (Baltimore). 2019 Nov;98(47):e18067. doi: 10.1097/MD.0000000000018067. PubMed 31764838 ↗
  • Bonnet N, Bourgoin L, Biver E, Douni E, Ferrari S. RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass. J Clin Invest. 2019 May 23;129(8):3214-3223. doi: 10.1172/JCI125915. PubMed 31120440 ↗
  • Weivoda MM, Chew CK, Monroe DG, Farr JN, Atkinson EJ, Geske JR, Eckhardt B, Thicke B, Ruan M, Tweed AJ, McCready LK, Rizza RA, Matveyenko A, Kassem M, Andersen TL, Vella A, Drake MT, Clarke BL, Oursler MJ, Khosla S. Identification of osteoclast-osteoblast coupling factors in humans reveals links between bone and energy metabolism. Nat Commun. 2020 Jan 7;11(1):87. doi: 10.1038/s41467-019-14003-6. PubMed 31911667 ↗
  • Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwinski E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017 Jul;5(7):513-523. doi: 10.1016/S2213-8587(17)30138-9. Epub 2017 May 22. PubMed 28546097 ↗
  • Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C; FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009 Aug 20;361(8):756-65. doi: 10.1056/NEJMoa0809493. Epub 2009 Aug 11. PubMed 19671655 ↗
  • Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK, San Martin J, Dansey R. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov. 2012 May;11(5):401-19. doi: 10.1038/nrd3705. PubMed 22543469 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — All results including inconclusive, positive, and negative results will be accessible to the public after the study has ended. As soon as possible and no later than one year after the trial has ended, the trial results will be submitted to the CTIS-portal.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Mar 2027, 33 months after the start.

Of 55 non-industry phase 4 interventional studies under Osteoporosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 71. This study's planned 33 months is below that.

Counting every sponsor, half of 65 studies reached it within 46 months; a quarter within 29 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Dec 9, 2025
StartActual
May 21, 2024
Primary completionEst.
Mar 1, 2027
CompletionEst.
Mar 1, 2027
Last update
Dec 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07271771
Collaborators
Sponsor: MD, Professor, DMSc, PhD Bente Lomholt Langdahl
Responsible party
Anne Sophie Sølling (MD, PhD, postdoc, Aarhus University Hospital) — Principal investigator
First posted
Dec 9, 2025
Start date
May 21, 2024
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Dec 15, 2025

Study contacts

Anne Sophie Sølling, MD, PhD
Contact
annesoel@rm.dk
+45 22 30 05 24
Bente Langdahl, MD, Professor, DMSc, PhD
principal investigator · Aarhus University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion